Drug
LACTIN-V
LACTIN-V is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
unknown125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition
NCT05022212
completedphase_2
Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
NCT00305227
unknownphase_1
The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
NCT03992534
completedphase_2
Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis
NCT00635622
Clinical Trials (4)
Showing 4 of 4 trials
NCT05022212Phase 2
Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition
NCT00305227Phase 2
Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
NCT03992534Phase 1
The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
NCT00635622Phase 2
Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4